Q3166648 (Q3166648): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): There are studies suggesting that individuals with the condition known as metabolically healthy obesity (MHO) may not have the same increase in risk for the development of metabolic abnormalities as their non-metabolically healthy counterparts. In addition, to date, the identification of metabolic biomarkers underlying the MHO state is limited. The objective of this study is to compare the metabolic profile, inflammatory parameters and mitochond...) |
||||||||||||||
| Property / summary | |||||||||||||||
There are studies suggesting that individuals with the condition known as metabolically healthy obesity (MHO) may not have the same increase in risk for the development of metabolic abnormalities as their non-metabolically healthy counterparts. In addition, to date, the identification of metabolic biomarkers underlying the MHO state is limited. The objective of this study is to compare the metabolic profile, inflammatory parameters and mitochondrial function, as well as the metabolomic analysis and differential expression of the microbiota in obese patients categorised as metabolically healthy vs. unhealthy. In parallel, the effect of the hypocaloric diet on metabolism and microbiota of obese subjects will be evaluated. Specifically, we propose an observational, clinical-basic, comparative and interventional study in a population of 80 obese patients (BMI>35 Kg/m²) characterised according to the presence of healthy or altered metabolism (altered fasting glycemia, hypertension, atherogenic dyslipemia). These patients will collect anthropometric and clinical variables and biological samples (serum, plasma, peripheral blood cells and faeces) for the determination of biochemical parameters (glucose, lipid and hormonal profile by enzymatic techniques) and peripheral protein-based biomarkers (total ROS and mitochondrial production, mitochondrial membrane potential, glutathione levels by static cytometry). markers of mitochondrial dynamics (MFN1, MFN2, FIS1 and DRP1 by Western Blot, RTPCR), markers of inflammation (IL6, TNFa, IL1b, adiponectin, resistin, PAI-1, MCP-1, shell 1 and NLRP3 by Western Blot, RT-PCR and XMAP technology), metabolomic analysis (MRI and PLS-DA spectroscopy), as well as the content and diversity of the intestinal microbiota (16S rRNA, MiSeq sequencing). Finally, we will evaluate the effect of a dietary intervention of weight loss on these biomarkers. (English) | |||||||||||||||
| Property / summary: There are studies suggesting that individuals with the condition known as metabolically healthy obesity (MHO) may not have the same increase in risk for the development of metabolic abnormalities as their non-metabolically healthy counterparts. In addition, to date, the identification of metabolic biomarkers underlying the MHO state is limited. The objective of this study is to compare the metabolic profile, inflammatory parameters and mitochondrial function, as well as the metabolomic analysis and differential expression of the microbiota in obese patients categorised as metabolically healthy vs. unhealthy. In parallel, the effect of the hypocaloric diet on metabolism and microbiota of obese subjects will be evaluated. Specifically, we propose an observational, clinical-basic, comparative and interventional study in a population of 80 obese patients (BMI>35 Kg/m²) characterised according to the presence of healthy or altered metabolism (altered fasting glycemia, hypertension, atherogenic dyslipemia). These patients will collect anthropometric and clinical variables and biological samples (serum, plasma, peripheral blood cells and faeces) for the determination of biochemical parameters (glucose, lipid and hormonal profile by enzymatic techniques) and peripheral protein-based biomarkers (total ROS and mitochondrial production, mitochondrial membrane potential, glutathione levels by static cytometry). markers of mitochondrial dynamics (MFN1, MFN2, FIS1 and DRP1 by Western Blot, RTPCR), markers of inflammation (IL6, TNFa, IL1b, adiponectin, resistin, PAI-1, MCP-1, shell 1 and NLRP3 by Western Blot, RT-PCR and XMAP technology), metabolomic analysis (MRI and PLS-DA spectroscopy), as well as the content and diversity of the intestinal microbiota (16S rRNA, MiSeq sequencing). Finally, we will evaluate the effect of a dietary intervention of weight loss on these biomarkers. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: There are studies suggesting that individuals with the condition known as metabolically healthy obesity (MHO) may not have the same increase in risk for the development of metabolic abnormalities as their non-metabolically healthy counterparts. In addition, to date, the identification of metabolic biomarkers underlying the MHO state is limited. The objective of this study is to compare the metabolic profile, inflammatory parameters and mitochondrial function, as well as the metabolomic analysis and differential expression of the microbiota in obese patients categorised as metabolically healthy vs. unhealthy. In parallel, the effect of the hypocaloric diet on metabolism and microbiota of obese subjects will be evaluated. Specifically, we propose an observational, clinical-basic, comparative and interventional study in a population of 80 obese patients (BMI>35 Kg/m²) characterised according to the presence of healthy or altered metabolism (altered fasting glycemia, hypertension, atherogenic dyslipemia). These patients will collect anthropometric and clinical variables and biological samples (serum, plasma, peripheral blood cells and faeces) for the determination of biochemical parameters (glucose, lipid and hormonal profile by enzymatic techniques) and peripheral protein-based biomarkers (total ROS and mitochondrial production, mitochondrial membrane potential, glutathione levels by static cytometry). markers of mitochondrial dynamics (MFN1, MFN2, FIS1 and DRP1 by Western Blot, RTPCR), markers of inflammation (IL6, TNFa, IL1b, adiponectin, resistin, PAI-1, MCP-1, shell 1 and NLRP3 by Western Blot, RT-PCR and XMAP technology), metabolomic analysis (MRI and PLS-DA spectroscopy), as well as the content and diversity of the intestinal microbiota (16S rRNA, MiSeq sequencing). Finally, we will evaluate the effect of a dietary intervention of weight loss on these biomarkers. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 17:05, 12 October 2021
Project Q3166648 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3166648 in Spain |
Statements
28,500.0 Euro
0 references
57,000.0 Euro
0 references
50.0 percent
0 references
1 January 2019
0 references
31 March 2022
0 references
FUNDACION PARA EL FOMENTO DE LA INV. SANITARIA Y BIOMEDICA DE LA COMUNIDAD VALENCIANA (FISABIO)
0 references
39°28'10.96"N, 0°22'34.82"W
0 references
46250
0 references
Existen trabajos que sugieren que los individuos con la condición conocida como obesidad metabólicamente sana (MHO) pueden no tener el mismo aumento en el riesgo para el desarrollo de anormalidades metabólicas como sus homólogos no metabólicamente sanos. Además, hasta la fecha, la identificación de biomarcadores metabólicos que subyacen al estado MHO es limitada. El objetivo de este estudio es comparar el perfil metabólico, los parámetros inflamatorios y la función mitocondrial, asi como el análisis metabolómico y la expresión diferencial de la microbiota en pacientes obesos categorizados como metabólicamente sanos vs no sanos. En paralelo, se evaluará el efecto de la dieta hipocalórica sobre el metabolismo y microbiota de los sujetos obesos. En concreto, planteamos un estudio observacional, clínico-básico, comparativo e intervencional en una población de 80 pacientes obesos (IMC>35 Kg/m2) caracterizados según la presencia de metabolismo sano o alterado (glucemia en ayunas alterada, hipertensión, dislipemia aterogénica). En estos pacientes se recogerán variables antropométricas y clínicas y muestras biológicas (suero, plasma, células sanguíneas periféricas y heces) para la determinación de parámetros bioquímicos (glucosa, perfil lipídico y hormonal por técnicas enzimáticas) y biomarcadores periféricos basados en proteínas (producción de ROS totales y mitocondrial, potencial de membrana mitocondrial, niveles de glutatión por citometría estática), marcadores de la dinámica mitocondrial (MFN1, MFN2, FIS1 y DRP1 por Western Blot, RTPCR), marcadores de inflamación (IL6, TNFa, IL1b, adiponectina, resistina, PAI-1, MCP-1,caspasa 1 y NLRP3 por Western Blot, RT-PCR y tecnología XMAP), el análisis metabolómico (espectroscopia de RMN y PLS-DA), asi como el contenido y la diversidad de la microbiota intestinal (16S rRNA, secuenciación MiSeq). Finalmente, evaluaremos el efecto de una intervención dietética de pérdida de peso sobre estos biomarcadores. (Spanish)
0 references
There are studies suggesting that individuals with the condition known as metabolically healthy obesity (MHO) may not have the same increase in risk for the development of metabolic abnormalities as their non-metabolically healthy counterparts. In addition, to date, the identification of metabolic biomarkers underlying the MHO state is limited. The objective of this study is to compare the metabolic profile, inflammatory parameters and mitochondrial function, as well as the metabolomic analysis and differential expression of the microbiota in obese patients categorised as metabolically healthy vs. unhealthy. In parallel, the effect of the hypocaloric diet on metabolism and microbiota of obese subjects will be evaluated. Specifically, we propose an observational, clinical-basic, comparative and interventional study in a population of 80 obese patients (BMI>35 Kg/m²) characterised according to the presence of healthy or altered metabolism (altered fasting glycemia, hypertension, atherogenic dyslipemia). These patients will collect anthropometric and clinical variables and biological samples (serum, plasma, peripheral blood cells and faeces) for the determination of biochemical parameters (glucose, lipid and hormonal profile by enzymatic techniques) and peripheral protein-based biomarkers (total ROS and mitochondrial production, mitochondrial membrane potential, glutathione levels by static cytometry). markers of mitochondrial dynamics (MFN1, MFN2, FIS1 and DRP1 by Western Blot, RTPCR), markers of inflammation (IL6, TNFa, IL1b, adiponectin, resistin, PAI-1, MCP-1, shell 1 and NLRP3 by Western Blot, RT-PCR and XMAP technology), metabolomic analysis (MRI and PLS-DA spectroscopy), as well as the content and diversity of the intestinal microbiota (16S rRNA, MiSeq sequencing). Finally, we will evaluate the effect of a dietary intervention of weight loss on these biomarkers. (English)
12 October 2021
0 references
Valencia
0 references
Identifiers
PI18_00932
0 references